Asian Paints

2876.6 16.80

Cipla

1511.8 -17.40

Eicher Motors

7134.5 9.00

Nestle India

1280.7 1.50

Grasim Inds

2734.8 -13.80

Hindalco Inds.

777.7 -22.10

Hind. Unilever

2433.7 5.30

ITC

407.85 2.40

Trent

4359.1 -29.80

Larsen & Toubro

4024.9 -12.50

M & M

3749.6 32.90

Reliance Industr

1546.6 -2.50

Tata Consumer

1183.1 9.20

Tata Motors PVeh

362.25 2.45

Tata Steel

168 -4.46

Wipro

244.49 -1.77

Apollo Hospitals

7391 -32.00

Dr Reddy's Labs

1243.9 -4.70

Titan Company

3904.2 1.80

SBI

972.6 -8.95

Shriram Finance

823.3 -3.30

Bharat Electron

416.35 -6.65

Kotak Mah. Bank

2087.8 -10.90

Infosys

1545 8.50

Bajaj Finance

1004.1 -24.50

Adani Enterp.

2422.3 -23.80

Sun Pharma.Inds.

1779.7 2.30

JSW Steel

1140.3 -29.70

HDFC Bank

998.05 -10.80

TCS

3150.6 5.80

ICICI Bank

1369.5 -13.50

Power Grid Corpn

277.6 0.40

Maruti Suzuki

15977 176.00

Axis Bank

1275.8 -9.40

HCL Technologies

1608 -37.40

O N G C

246.95 -1.10

NTPC

326.65 0.05

Coal India

378.2 -1.45

Bharti Airtel

2162.7 4.40

Tech Mahindra

1461.5 5.50

Jio Financial

303.55 -4.80

Adani Ports

1479.8 -11.30

HDFC Life Insur.

764 1.80

SBI Life Insuran

2022.5 -4.60

Max Healthcare

1181.1 12.20

UltraTech Cem.

11729 -24.00

Bajaj Auto

8892 -87.50

Bajaj Finserv

2052.4 -43.20

Interglobe Aviat

5843.5 58.00

Eternal Ltd

301.95 -4.95

Corporate News - Detailed News Back
Shilpa Medicare's Unit IV completes USFDA inspection
22-Nov-25   12:02 Hrs IST
Shilpa Medicare announced that USFDA Inspection of Shilpa Medicare, Unit IV, Jadcherla, Telangana, India has been completed on 21 November 2025. The ten day inspection ended with the issuance of FDA Form 483 with eight inspectional observations none of which has been categorized as a repeat observation.

This facility is capable of manufacturing, packaging, testing, storage and distribution of sterile injectables, oral tablets and Capsules, and is supplying to US, Europe and other markets across the globe. The US sales of products manufactured at this plant was less than 1% of the total business of the company for the first half year of FY25-26 and less than 5% of the total business of the company for FY24-25.

The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia.

Powered by Capital Market - Live News


DJIA 46275.21
501.96 1.10%
S&P 500 6624.30
64.54 0.98%
HANG SENG 25220.03
-615.55 -2.38%
NIKKEI 225 48653.14
-1170.80 -2.35%
FTSE 100 9535.95
8.30 0.09%
NIFTY 26068.15
-124.00 -0.47%
×
Ask Your Question
close
refresh